ABBVIE
A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®)
- Conditions
- Polyarticular Juvenile Arthritis
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 70
- Registration Number
- NCT03383263
- Locations
- 🇷🇺
Chelyabinsk Regional Children's Clinical Hospital /ID# 204829, Chelyabinsk, Chelyabinskaya Oblast, Russian Federation
🇷🇺Republican Children's Clinical Hospital /ID# 204830, Ufa, Bashkortostan, Respublika, Russian Federation
🇷🇺Saratov State Medical University n.a. V.I. Razumovskiy /ID# 206319, Saratov, Saratovskaya Oblast, Russian Federation
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
- Conditions
- Parkinson's Disease (PD)
- Interventions
- Drug: ABBV-951
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT03374917
- Locations
- 🇺🇸
Univ Kansas Med Ctr /ID# 166280, Kansas City, Kansas, United States
🇺🇸Loma Linda University /ID# 165592, Loma Linda, California, United States
🇺🇸Compass Research /ID# 167329, Orlando, Florida, United States
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 70
- Registration Number
- NCT03368859
- Locations
- 🇺🇸
USC Norris Cancer Center /ID# 200410, Los Angeles, California, United States
🇺🇸University of California, Los /ID# 169294, Santa Monica, California, United States
🇺🇸Florida Cancer Specialist - South /ID# 203796, Fort Myers, Florida, United States
COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel
- Conditions
- Parkinson's Disease (PD)
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 412
- Registration Number
- NCT03362879
- Locations
- 🇷🇴
Colentina Clinical Hospital /ID# 169263, Bucharest, Romania
🇷🇴Emergency Clinical County Hosp /ID# 169269, Targu Mures, Romania
🇨🇦Ottawa Hospital /ID# 169448, Ottawa, Ontario, Canada
A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Drug: ABBV-744
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT03360006
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center /ID# 160701, Houston, Texas, United States
🇺🇸Northwestern /ID# 171098, Chicago, Illinois, United States
🇺🇸University of California, Davis Comprehensive Cancer Center /ID# 202729, Sacramento, California, United States
A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain
- Conditions
- Endometriosis
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 11
- Registration Number
- NCT03343067
- Locations
- 🇺🇸
Quad Clinical Research, LLC /ID# 168294, Chicago, Illinois, United States
🇺🇸Seattle Reproductive Medicine /ID# 171079, Seattle, Washington, United States
🇺🇸Central Ohio Clinical Research /ID# 170750, Columbus, Ohio, United States
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 747
- Registration Number
- NCT03345823
- Locations
- 🇺🇸
Baylor Scott & White Center for Inflammatory Bowel Diseases /ID# 170161, Dallas, Texas, United States
🇺🇸Duplicate_Rush University Medical Center /ID# 165470, Chicago, Illinois, United States
🇺🇸University of Washington /ID# 164646, Seattle, Washington, United States
A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 526
- Registration Number
- NCT03345849
- Locations
- 🇦🇺
Fiona Stanley Hospital /ID# 171513, Murdoch, Western Australia, Australia
🇺🇸Velocity Clinical Research - Salt Lake City /ID# 166076, West Jordan, Utah, United States
🇺🇸Rush University Medical Center /ID# 165497, Chicago, Illinois, United States
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
- Conditions
- Crohn's Disease
- Interventions
- Drug: Matching Placebo for UpadacitinibDrug: Upadacitinib
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 624
- Registration Number
- NCT03345836
- Locations
- 🇦🇷
Cardio Alem /ID# 211284, San Isidro, Buenos Aires, Argentina
🇺🇸Facey Medical Foundation /ID# 203137, Mission Hills, California, United States
🇺🇸CB Flock Research Corporation /ID# 166220, Mobile, Alabama, United States
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 350
- Registration Number
- NCT03342144
- Locations
- 🇦🇹
Hanusch Krankenhaus /ID# 221151, Wien, Austria
🇩🇪Praxis Dr. Kreher /ID# 202604, Bad Liebenwerda, Brandenburg, Germany
🇩🇪Friedrich-Ebert-Krankenhaus GmbH /ID# 206206, Neumuenster, Schleswig-Holstein, Germany